



1 February 2016

AIM: RENE

ReNeuron Group plc

ReNeuron receives notice of grant of key US patent on its cell cryopreservation technology

Guildford, UK, 1 February 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology.

The patent application, “Cellular Compositions for use in Therapy” (No. 13/132,475), contains broad claims relating to cryopreserved neural, retinal and mesenchymal stem cells using a formulation developed by ReNeuron researchers that, uniquely, is free of toxic cryopreservants.

ReNeuron has deployed its cryopreservation technology to its lead *CTX* stem cell line to derive a cryopreserved, long shelf life cell therapy candidate, designated *CTXcryo*. The Company has received regulatory approval to use *CTXcryo*, with a current six-month shelf life, in its ongoing UK clinical trials in both stroke disability and critical limb ischaemia.

ReNeuron believes that its patented *CTXcryo* product will provide the Company with significant commercial and competitive advantages in terms of the availability of a genuine off-the-shelf, low cost-of-goods cell therapy candidate with a shelf life enabling shipping to, and storage at, clinical sites on a global basis.

Equivalent patents to the allowed US patent have already issued in Europe, Japan and Australia.

ReNeuron has broad and multi-layered patent protection covering all of its cell-based technologies and therapeutic candidates. The Company owns or has exclusively licensed more than 80 issued patents, providing protection for its technologies in key potential markets across the globe.

Olav Hellebø, Chief Executive Officer of ReNeuron, said:

“The US Notice of Allowance for our cell cryopreservation technology is an important further addition to ReNeuron’s extensive patent estate. We have invested heavily in patents over the years, an investment that we believe will

provide significant returns for the Company as our technologies and therapeutic candidates approach commercialisation.”

Enquiries:

ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer

Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson

Cenkos Securities +44 (0) 20 7397 8900
Stephen Keys, Dr Christopher Golden (NOMAD and
Broker)
Russell Kerr (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding

the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.